Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24536778 | 0.93 | KRAS (0.48) | KRAS | |
| SCHEMBL29680489 | 0.88 | KRAS (0.52) | KRAS | |
| SCHEMBL24536826 | 0.88 | KRAS (0.52) | KRAS | |
| SCHEMBL29680343 | 0.88 | KRAS (0.70) | KRAS | |
| SCHEMBL24536723 | 0.88 | KRAS (0.70) | KRAS | |
| SCHEMBL24536172 | 0.83 | KRAS (0.61) | KRAS | |
| SCHEMBL29679985 | 0.83 | KRAS (0.61) | KRAS | |
| SCHEMBL24535674 | 0.83 | KRAS (0.48) | KRAS | |
| SCHEMBL31323528 | 0.83 | KRAS (0.62) | KRAS | |
| SCHEMBL24535669 | 0.83 | KRAS (0.74) | KRASMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885MAPK3 286/4885MAPK1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.